Aptose Biosciences Inc. 8-K Report Insights for February 7, 2025

Here are the key insights extracted from the provided section of the financial report:

1. Entity Information:

• Company Name: Aptose Biosciences Inc.
• CIK (Central Index Key): 0000882361
• SEC File Number: 001-32001
• EIN (Employer Identification Number): 98-1136802
• Address: 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, ON, Canada, M5K 1E6
• Contact Number: (647) 479-9828

2. Filings and Reporting:

• Filing Type: 8-K
• Filing Date: February 7, 2025

3. Stock Information:

• Common Shares: The company has issued common shares with no par value.

4. Reporting Context:

• Period Covered: The report covers a single day, February 7, 2025.

5. Exchange Listing:

• The company is listed on NASDAQ.

6. XML and XBRL Details:

• The document is formatted in XML and XBRL, indicating it is intended for electronic filing with the SEC.

Insights:

• The filing indicates that Aptose Biosciences Inc. is actively reporting to the SEC, which is important for investors and stakeholders to monitor.
• The date of the filing suggests that it may contain critical updates or events that occurred on that specific day, which could influence stock performance or investor sentiment.
• As a biotechnology firm, any developments reported in an 8-K filing could be significant, potentially relating to clinical trial results, partnerships, or financial updates.

This summary provides a concise overview of the company's reporting and essential details relevant for analysis or decision-making.